Trailing-twelve-month (TTM) revenue is $431.80 Million with a year-over-year growth of +19.19%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q4 FY2025Period ended 2025-09-30 | $99,009,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-17 |
| Q1 FY2026Period ended 2025-12-31 | $103,698,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-02 |
| Q2 FY2026Period ended 2026-03-31 | $110,715,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-04 |
| Q3 FY2026Period ended 2026-06-30 | $118,376,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-03 |
| TTM revenue | $431,798,000 |
Current P/S: $10,397,438,961 market capitalization ÷ $431,798,000 TTM revenue = 24.08x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q3 FY2026 (2026-06-30): $118.38M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T22:24:03.500Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-09-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-09-30 · USD | FY20212021-09-30 · USD | FY20222022-09-30 · USD | FY20232023-09-30 · USD | FY20242024-09-30 · USD | FY20252025-09-30 · USD |
|---|---|---|---|---|---|---|
| Antibody Discovery | N/A | N/A | $24M | $23M | $20M | $23M |
| Dna And Biopharma Libraries | N/A | $13M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-09-30 · USD | FY20212021-09-30 · USD | FY20222022-09-30 · USD | FY20232023-09-30 · USD | FY20242024-09-30 · USD | FY20252025-09-30 · USD |
|---|---|---|---|---|---|---|
| Americas | $1M | $78M | $122M | $151M | $194M | $226M |
| Asia Pacific | $5M | $10M | $19M | $22M |
$431.80M
$431.80 Million
+19.19%
vs. $362.28M a year ago (TTM)
+27.77%
5 Year compound annual growth rate
1 Year
+19.19%
3 Year
+22.39%
5 Year
+27.77%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $376.57M | +$63.60M | +20.32% |
| 2024 | $312.97M | +$67.86M | +27.69% |
| 2023 | $245.11M | +$41.54M | +20.41% |
| 2022 | $203.56M | +$71.23M | +53.83% |
| 2021 | $132.33M | +$42.23M | +46.87% |
| 2020 |
TTM Growth
+19.19%
3-Year CAGR
+22.39%
5-Year CAGR
+27.77%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 31 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T22:24:03.500Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-09-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $10M |
| $14M |
| $11M |
| DNA And Biopharma Libraries | $6M | N/A | N/A | N/A | N/A | N/A |
|---|
| Ngs Tools | N/A | $73M | $99M | $124M | $169M | $208M |
|---|
| NGS Tools | $44M | N/A | N/A | N/A | N/A | N/A |
|---|
| Oligo Pools | $5M | $8M | $12M | $14M | $17M | $20M |
|---|
| Synthetic Genes | $35M | $39M | $62M | $74M | $93M | $114M |
|---|
| $27M |
| E M E A | N/A | $44M | N/A | N/A | N/A | N/A |
|---|
| EMEA | $26M | N/A | $62M | $71M | $93M | $124M |
|---|
| UNITED STATES | $58M | N/A | N/A | N/A | N/A | N/A |
|---|
| $90.10M |
| +$35.72M |
| +65.67% |
| 2019 | $54.38M | +$28.96M | +113.89% |
| 2018 | $25.43M | +$14.66M | +136.16% |
| 2017 | $10.77M | +$8.50M | +374.53% |
